Target intelligence / Profile preview

N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL)

Target: PIGL
Molecular classification: Enzyme, Glycosyltransferase-related enzyme

Overview

N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL) is an enzyme that catalyzes the second step of glycosylphosphatidylinositol (GPI) anchor biosynthesis, specifically the de-N-acetylation of N-acetylglucosaminyl-phosphatidylinositol. This reaction is essential for the assembly of GPI anchors, which attach numerous proteins to the cell membrane. Altered PIGL activity can disrupt proper cell surface protein localization and has been linked to cancer immune evasion mechanisms as well as congenital disorders of glycosylation.

Other names: Phosphatidylinositol glycan anchor biosynthesis class LPIG-LPhosphatidylinositol-glycan biosynthesis class L proteinN-acetylglucosaminylphosphatidylinositol deacetylaseCHIME

Mechanism of action

Potential mechanism: inhibition or genetic manipulation could affect GPI-anchor biosynthesis, influencing cell surface protein display and immune response

Biological functions

Glycosylphosphatidylinositol (GPI) anchor biosynthesisDe-N-acetylation of N-acetylglucosaminyl-phosphatidylinositolProtein anchoring to membranes

Disease associations

Cancer (linked to immune evasion and checkpoint therapy sensitivity)Congenital disorders of glycosylation (mutation associated)

Safety considerations

Loss-of-function or mutations cause congenital glycosylation disordersDisruption may impact immune system function or cellular protein targeting

Biomarkers

PIGL alterations (expression or functional mutations) may serve as research biomarkers in cancers or congenital glycosylation disorders

Beyond the preview

Go deeper on N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase (PIGL).

Explore the full profile